Seth L. Toback

Adolescent Medicine | Emergency Medicine

19450 Deerfield Avenue
Suite 200
Leesburg, VA 20176

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Real-world effectiveness and safety of protein-based and mRNA COVID-19 vaccines (BEEHIVE trial).

Real-world effectiveness and safety of protein-based and mRNA COVID-19 vaccines (BEEHIVE trial).

Journal: Vaccine

Published: April 07, 2026

The shadow of reactogenicity: Parental hesitancy due to prior vaccine experiences.

The shadow of reactogenicity: Parental hesitancy due to prior vaccine experiences.

Journal: Vaccine

Published: August 08, 2025

Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).

Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).

Journal: Vaccine

Published: September 09, 2024

Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines.

Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines.

Journal: Vaccines

Published: June 18, 2024

Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study.

Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study.

Journal: Vaccines

Published: December 08, 2023

Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.

Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.

Journal: Vaccine

Published: September 26, 2023

The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review.

The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review.

Journal: The Journal of infectious diseases

Published: July 14, 2023

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines.

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines.

Journal: Expert review of vaccines

Published: June 30, 2023

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.

Journal: Expert review of vaccines

Published: May 29, 2023

NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.

NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.

Journal: Vaccine

Published: March 17, 2023

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: July 07, 2022

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.

Journal: The New England journal of medicine

Published: June 30, 2021

Showing 1-12 of 34

Last Updated: 09/26/2026